Improving the Quality of Care for Patients Harboring ALK+ NSCLC
CME activity here: https://reachmd.com/programs/cme/improving-quality-care-patients-harboring-alk-nsclc/12631/ This CME activity will review molecular testing for ALK rearrangements, approved and emerging therapeutic options for the first-line treatment of ALK+ NSCLC and treatment upon disease progression, treatment selection and sequencing, and efficacy and safety data of ALK inhibitors. Comments are closed.
|
Author@DrJosephKim Sign up to receive updates:
|